netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Chapter Links...
 Details...
05.03.03.02  Expand sub section  Chronic hepatitis C
Boceprevir (Victrelis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of genotype 1 chronic hepatitis C as per NICE TA253.

Funded by specialised commissioning.

APCO May 2012.

 
Link  NICE TA253: hepatitis
Link  MHRA: predicting sepsis, worsening liver function & mortality with boceprevir & telaprevir
   
Daclatasvir  (Daklinza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of hepatitis C as per NICE TA364 and NHSE B07/P/a policy.

Funded by specialised commissioning.

APCO January 2016.

 
Link  NICE TA364: Daclatasvir for treating chronic hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
   
Dasabuvir (Exviera®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

In combination with ombitasvir-paritaprevir-ritonavir for treating chronic hepatitis C as per NICE TA365.

Funded by specialised commissioning.

APCO January 2016.

 
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
   
Elbasvir and Grazoprevir (Zepatier®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For treating chronic hepatitis C as per NICE TA413.

Funded by specialised commissioning.

APCO November 2016.

 
Link  NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
   
Glecaprevir and Pibrentasvir (Maviret®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating chronic hepatitis C as per NICE TA499.

APCO March 2018.

 
Link  NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
   
Ledipasvir and Sofosbuvir (Harvoni®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For treating chronic hepatitis C as per NICE TA363.

Funded by specialised commissioning.

APCO January 2016.

 
Link  NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
Link  MHRA: Avoid use of amiodarone with sofosbuvir
   
Ombitasvir - Paritaprevir - Ritonavir (Viekirax®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

With or without dasabuvir for treating chronic hepatitis C as per NICE TA365.

Funded by specialised commissioning.

APCO January 2016.

 
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
   
Simeprevir (Olysio®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

In combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C as per NICE TA331.

Funded by specialised commissioning.

APCO March 2015.

 
Link  NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
Link  MHRA: Avoid use of amiodarone with simeprevir
   
Sofosbuvir (Sovaldi®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine

Red Traffic Light  For the treatment of hepatitis C as per NICE TA330 and NHS England policy B07/P/a. Funded by specialised commissioning. 

APCO March 2015.

Black Traffic Light  In combination with simeprevir for treating genotype 1 or 4 chronic hepatitis C (NICE TA330 - terminated appraisal).

APCO November 2015.

 
Link  NICE TA330: Sofosbuvir for treating chronic hepatitis C
Link  Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis (NHS England B07/P/a)
Link  MHRA: Avoid use of amiodarone with sofosbuvir
   
Sofosbuvir - Velpatasvir - Voxilaprevir (Vosevi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating chronic hepatitis C as per NICE TA507.

APCO March 2018.

 
Link  NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
   
Sofosbuvir and Velpatasvir (Epclusa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For treating chronic hepatitis C as per NICE TA430.

Funded by specialised commissioning.

APCO March 2017.

 
Link  NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
   
Telaprevir (Incivo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of genotype 1 chronic hepatitis C as per NICE TA252.

Funded by specialised commissioning.

APCO May 2012.

 
Link  NICE TA252: Telaprevir in hepatitis C
Link  MHRA: predicting sepsis, worsening liver function & mortality with boceprevir & telaprevir
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary